Hemophilia – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025
Hemophilia Emerging Therapy and TPP Insights Thelansis’s “Hemophilia Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Hemophilia Overview Hemophilia is a rare inherited bleeding disorder caused by a deficiency or dysfunction of clotting factors, most commonly factor VIII (hemophilia A) or factor IX (hemophilia B). The condition is X‑linked, primarily affecting males, and is characterized by prolonged bleeding after injury, frequent bruising, and spontaneous hemorrhages into joints and muscles that can lead to chronic pain and disability. Severity depends on the level of clotting factor activity, with severe cases presenting early in life and mild forms sometimes detected only after surgery or trauma. Diagnosis is confirmed...